Lantheus

Lantheus

Yahoo Finance • 15 days ago

Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s

[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults... Full story

Yahoo Finance • 25 days ago

Halper Sadeh LLC is Investigating Whether MKTX, SMTI, LNTH are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • 25 days ago

Curium to acquire Lantheus in all-cash deal worth up to $8bn

CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn. The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will... Full story

Yahoo Finance • 25 days ago

1 Healthcare Stock Worth Your Attention and 2 We Question

1 Healthcare Stock Worth Your Attention and 2 We Question From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong fina... Full story

Yahoo Finance • 26 days ago

Halper Sadeh LLC is Investigating Whether LNTH, ATKR, INDV are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • 26 days ago

Curium deepens radiopharma heft with up to $8 billion deal for Lantheus

By Kamal Choudhury and Kunal Das Aug 3 (Reuters) - Radiopharmaceutical company Curium has agreed to buy peer Lantheus Holdings in a deal worth up to $8 ‌billion, as the private equity-backed firm looks to expand its footprint in ‌the fast... Full story

Yahoo Finance • 29 days ago

Biotech Stocks Facing FDA Decision In August 2026

(RTTNews) - As we head into August, it's time for our monthly roundup of the upcoming FDA decisions that could move biotech stocks. The August regulatory calendar spans a wide range of indications - from the ultra-rare Fibrodysplasia Ossi... Full story

Yahoo Finance • 2 months ago

Q2 watchlist: Healthcare stocks with perfect EPS revision scores

[Heart Health Concept] Eoneren/E+ via Getty Images As Q2 2026 earnings season approaches, healthcare stocks are drawing investor attention as markets assess demand across care delivery, diagnostics, life sciences, pharmaceuticals, medical... Full story

Yahoo Finance • 2 months ago

Lantheus receives Complete Response Letter for LNTH-2501

[US Food and Drug Administration (FDA)] * The US FDA issued a Complete Response Letter to Lantheus (LNTH [https://seekingalpha.com/symbol/LNTH]) for LNTH-2501, its PET diagnostic imaging kit targeting somatostatin receptor-positive (SST... Full story

Yahoo Finance • 2 months ago

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to del... Full story

Yahoo Finance • 3 months ago

3 Healthcare Stocks with Open Questions

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 6.4% over the past s... Full story

Yahoo Finance • 3 months ago

1 Cash-Producing Stock on Our Buy List and 2 Facing Challenges

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luckily for you, we built StockStory to help you separate the good from the bad. Kee... Full story

Yahoo Finance • 3 months ago

Why This Fund Cashed Out of a Stock That Soared 250% in Just One Year

On May 14, 2026, Brigade Capital Management disclosed in an SEC filing that it sold out of Nabors Industries(NYSE:NBR), unloading 675,879 shares for an estimated $49.04 million based on quarterly average pricing. What happened According... Full story

Yahoo Finance • 3 months ago

Lantheus Holdings gains after report it's evaluating a sale after offer

[M&A Mergers And Acquisitions] narvo vexar Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) quickly rose 7.4% on a report that it's evaluating a sale after receiving a takeover offer from Curium that values the radiopharma... Full story

Yahoo Finance • 4 months ago

1 Healthcare Stock to Target This Week and 2 We Ignore

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag... Full story

Yahoo Finance • 5 months ago

3 Cash-Producing Stocks Walking a Fine Line

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. Luckily for you, we built StockStory t... Full story

Yahoo Finance • 5 months ago

Jefferies Lifts PT on Lantheus Holdings (LNTH) to $110 From $105 – Here’s Why

Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the best high growth healthcare stocks to buy now. On March 17, Jefferies lifted the price target on Lantheus Holdings, Inc. (NASDAQ:LNTH) to $110 from $105, reaffirming a Buy rating on the s... Full story

Yahoo Finance • 6 months ago

Why Lantheus (LNTH) Is Up 5.4% After Dual FDA Wins In Radiopharmaceutical Oncology Expansion

Lantheus Holdings recently received FDA approval for PYLARIFY TruVu, an enhanced formulation of its PSMA PET imaging agent designed to improve manufacturing efficiency and geographic reach for prostate cancer diagnostics. The company also... Full story

Yahoo Finance • 6 months ago

Why Lantheus Holdings Stock Popped by Almost 12% Last Month

Key Points Although its adjusted net income dipped, it handily beat analyst expectations on both the top and bottom lines. It also announced a very sensible pivot in its business.10 stocks we like better than Lantheus › February is a fri... Full story

Yahoo Finance • 6 months ago

Lantheus : FDA Approves PYLARIFY TruVu, New PSMA Imaging Agent For Prostate Cancer

(RTTNews) - Lantheus Holdings Inc. (LNTH) announced that the U.S. Food and Drug Administration has approved PYLARIFY TruVu (piflufolastat F 18) injection, a new formulation of its F 18 prostate-specific membrane antigen (PSMA) imaging agen... Full story